Kodiak Sciences Inc. (KOD), a biopharmaceutical company focused on developing transformative therapies for retinal diseases, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:00 p.m. PT / 6:00 p.m. ET.
The company has made significant progress with its investigational drugs - Tarcocimab tedromer, KSI-501 and KSI-101.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com